🇺🇸 FDA
Pipeline program

haploid allogeneic NK cell therapy

DS2019070101

Phase 1 mab active

Quick answer

haploid allogeneic NK cell therapy for Acute Myeloid Leukemia is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Acute Myeloid Leukemia
Phase
Phase 1
Modality
mab
Status
active

Clinical trials